Bipolar Disorder

• CLINICAL_TRIALS safety_alert · 2025-10-21
  Clinical Trial Update: Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

  An observational safety study evaluating ADASUVE (loxapine inhalation powder) for agitation associated with schizophrenia or Bipolar I disor…

• EMA safety_alert · 2024-01-26
  Precautionary measures to address potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines

  EMA safety precautionary measures advise restricting valproate use in men prior to conception due to possible risk of neurodevelopmental dis…

• EMA safety_alert · 2018-02-09
  PRAC recommends new measures to avoid valproate exposure in pregnancy

  The PRAC recommends new measures to prevent valproate exposure during pregnancy due to risks of birth defects and developmental problems in …

• EMA safety_alert · 2017-07-11
  EMA seeks views of public during its safety review of valproate

  EMA is seeking public input as part of its safety review of valproate, focusing on potential risks and safer use to protect patients, partic…

• CLINICAL_TRIALS safety_alert · 2010-01-12
  Clinical Trial Update: Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine [Phase 4]

  A Phase 4 clinical trial update reports heart rate changes in patients with schizophrenia or bipolar disorder treated with aripiprazole or q…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS safety_alert · 2009-01-27
  Clinical Trial Update: Changes in Heart Rhythms Associated With Antipsychotic Drug Treatment

  A clinical trial update reports changes in heart rhythms associated with antipsychotic drug treatment, highlighting potential cardiac safety…